Home › Research › Brain tissue and pathology
α-synuclein as an emerging pathophysiological biomarker of Alzheimer's disease
Maria Francesca Beatino, Ciro De Luca, Nicole Campese, Elisabetta Belli, Rebecca Piccarducci, Linda Giampietri, Claudia Martini, Giulio Perugi et al.. Expert review of molecular diagnostics, 2022-05-06
Topic: Plasma and spinal-fluid biomarkers
INTRODUCTION: α-syn aggregates represent the pathological hallmark of synucleinopathies as well as a frequent copathology (almost 1/3 of cases) in AD. Recent research indicates a potential role of α-syn species, measured in CSF with conventional analytical techniques, in the differential diagnosis between AD and synucleinopathies (such as DLB). Pioneering studies report the detection of α-syn in blood, however, conclusive investigations are controversial. Ultrasensitive seed amplification techniques, enabling the selective quantification of α-syn seeds, may represent an effective solution to identify the α-syn component in AD and facilitate a biomarker-guided stratification. AREAS COVERED: We performed a PubMed-based review of the latest findings on α-syn-related biomarkers for AD, focusing on bodily fluids. A dissertation on the role of ultrasensitive seed amplification assays, detecting α-syn seeds from different biological samples, was conducted. EXPERT OPINION: α-syn may contribute to progressive AD neurodegeneration through cross-seeding especially with tau protein. Ultrasensitive seed amplification techniques may support a biomarker-drug co-development pathway and may be a pathophysiological candidate biomarker for the evolving ATX(N) system to classify AD and the spectrum of primary NDDs. This would contribute to a precise approach to AD, aimed at implementing disease-modifying treatments.
Key findings
- AREAS COVERED: We performed a PubMed-based review of the latest findings on α-syn-related biomarkers for AD, focusing on bodily fluids.
- A dissertation on the role of ultrasensitive seed amplification assays, detecting α-syn seeds from different biological samples, was conducted.
- EXPERT OPINION: α-syn may contribute to progressive AD neurodegeneration through cross-seeding especially with tau protein.
- Ultrasensitive seed amplification techniques may support a biomarker-drug co-development pathway and may be a pathophysiological candidate biomarker for the evolving ATX(N) system to classify AD and the spectrum of primary NDDs.
- This would contribute to a precise approach to AD, aimed at implementing disease-modifying treatments.
Study details
- Evidence strengthLow
How this study scored 41/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multi-centre collaboration and free to read, so those were left out: it earned 23 of the 56 points we could judge it on, which is 41 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Expert review of molecular diagnostics) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 35443850) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 23 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 23 of the 56 points we could judge it on is 41 out of 100. |
| Total | 41 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
APA 7th
Beatino, M. F., De Luca, C., Campese, N., Belli, E., Piccarducci, R., Giampietri, L., et al. (2022). α-synuclein as an emerging pathophysiological biomarker of Alzheimer's disease. Expert review of molecular diagnostics. https://doi.org/10.1080/14737159.2022.2068952
Vancouver
Beatino MF, De Luca C, Campese N, Belli E, Piccarducci R, Giampietri L, et al. α-synuclein as an emerging pathophysiological biomarker of Alzheimer's disease. Expert review of molecular diagnostics. 2022. doi:10.1080/14737159.2022.2068952. PMID: 35443850.
BibTeX
@article{beatino2022-35443850,
author = {Beatino, Maria Francesca and De Luca, Ciro and Campese, Nicole and Belli, Elisabetta and Piccarducci, Rebecca and Giampietri, Linda and Martini, Claudia and Perugi, Giulio and others},
title = {{α-synuclein as an emerging pathophysiological biomarker of Alzheimer's disease}},
journal = {Expert review of molecular diagnostics},
year = {2022},
doi = {10.1080/14737159.2022.2068952},
pmid = {35443850},
url = {https://doi.org/10.1080/14737159.2022.2068952}
}
Related studies in Brain tissue and pathology
Also tagged “blood-based”
698 studies in the library carry the topic tag “blood-based”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 698 tagged studies.